MK-5475 is an experimental soluble guanylate cyclase stimulator which is administered via dry powder inhalation and is designed to potentially mitigate the side effects associated with systemic vasodilation.
The results of the INSIGNIA-PAH study published in the Respiratory Journal suggest that MK-5475 reduced pulmonary vascular resistance (PVR) and was well tolerated in patients with pulmonary arterial hypertension, without evidence of systemic side-effects such as hypotension, suggesting a pulmonary selective pharmacodynamic effect.
Read more at this link on the ERS Respiratory Journal web page.
Citation
Marc Humbert, Paul M. Hassoun, Kelly M. Chin, Guillermo Bortman, Mahesh J. Patel, Carmen La Rosa, Wei Fu, Maria José Loureiro, Marius M. Hoeper, European Respiratory Journal 2024; DOI: 10.1183/13993003.01110-2024